Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A morphologic variant of hepatocellular carcinoma characterized by the presence of clear cells.
Biomarker and diagnostic research for hepatocellular clear cell carcinoma has been reported in the published literature.
No clinical trials have been registered for hepatocellular clear cell carcinoma.
253 publications have been identified in PubMed for hepatocellular clear cell carcinoma. Kisho has analyzed 152 by research type. Research spans Basic Science / Preclinical (54%), Diagnostic / Biomarker (16%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 82 | 54% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Testing and diagnosis research |
24 |
16% |
Research summaries | 16 | 11% |
New treatment approaches | 11 | 7% |
Patient case studies | 7 | 5% |
Clinical study results | 6 | 4% |
Disease patterns and progression | 6 | 4% |
Yang X (2026). [PMID: 41932001](https://pubmed.ncbi.nlm.nih.gov/41932001/). *Phytomedicine*. [Review / Meta-Analysis]
Cosner Z (2026). [PMID: 41984885](https://pubmed.ncbi.nlm.nih.gov/41984885/). *Clin Cancer Res*. [Clinical Trial Publication]
Phan NH (2026). [PMID: 41769513](https://pubmed.ncbi.nlm.nih.gov/41769513/). *Cureus*. [Case Report / Case Series]
Yu F (2026). [PMID: 41995675](https://pubmed.ncbi.nlm.nih.gov/41995675/). *Hum Vaccin Immunother*. [Review / Meta-Analysis]
Wen S (2026). [PMID: 41165836](https://pubmed.ncbi.nlm.nih.gov/41165836/). *Naunyn Schmiedebergs Arch Pharmacol*. [Basic Science / Preclinical]
Febres-Aldana CA (2026). [PMID: 41580239](https://pubmed.ncbi.nlm.nih.gov/41580239/). *Mod Pathol*. [Basic Science / Preclinical]
Kolenda T (2026). [PMID: 42110626](https://pubmed.ncbi.nlm.nih.gov/42110626/). *Arch Med Sci*. [Basic Science / Preclinical]
Wei C (2026). [PMID: 42137460](https://pubmed.ncbi.nlm.nih.gov/42137460/). *Oncol Lett*. [Epidemiology / Natural History]
Yang Z (2026). [PMID: 41699549](https://pubmed.ncbi.nlm.nih.gov/41699549/). *BMC Cancer*. [Review / Meta-Analysis]
Yang YL (2026). [PMID: 42065054](https://pubmed.ncbi.nlm.nih.gov/42065054/). *Oncol Res*. [Diagnostic / Biomarker]
AI-curated news mentioning hepatocellular clear cell carcinoma
Updated Sep 17, 2026
A new study presents a noninvasive model for predicting clinically significant portal hypertension in patients with hepatocellular carcinoma. This tumor-adjusted approach could enhance patient management and treatment strategies.
Research reveals that Mint3 modulates the AHR signaling pathway to suppress cuproptosis, thereby facilitating the progression of hepatocellular carcinoma. This discovery could inform future therapeutic strategies targeting this cancer.
A recent pathological study highlights the distinct growth patterns between hepatic alveolar echinococcosis and hepatocellular carcinoma. This research could inform future diagnostic and treatment strategies for these conditions.
BeOne Medicines has received a UK innovation passport for its investigational antibody therapy targeting hepatocellular carcinoma (HCC), facilitating accelerated access to the treatment. This designation underscores the potential of the therapy in addressing a critical need in cancer care.